Venture Capital Funds Backing Xenex Disinfection Services

Xenex Disinfection Services is a company that develops and manufactures UV light disinfection robots to assist hospitals in reducing Hospital-Acquired Infections (HAIs). The company was founded in 2009 by Mark Tuck Stibich and Julie Stachowiak, who met during their doctoral studies at Johns Hopkins University. Xenex's technology is designed to destroy harmful microorganisms and reduce the bacterial load associated with HAIs, thereby improving patient health and satisfaction. Since its commercial launch in 2010, Xenex's devices have been implemented in almost 300 hospitals across the United States. The company has raised $95.32 million over seven funding rounds, with investors including EW Healthcare Partners, Essex Woodlands, and Piper Jaffray Merchant Banking. In this paragraph, we will explore which venture capital funds have invested in Xenex Disinfection Services and the impact of their innovative technology on healthcare facilities.

Xenex's UV light disinfection robots

Xenex Disinfection Services, headquartered in San Antonio, Texas, offers an innovative approach to reducing healthcare-acquired infections (HAIs) with its Pulsed Xenon Full Spectrum UV Disinfection Solution. This solution is designed to destroy harmful microorganisms and reduce the bacterial load associated with increased infection risk.

Xenex's Germ-Zapping Robot, at the core of their disinfection system, employs a patented Pulsed Xenon UV technology to break the chain of pathogen transmission in healthcare settings. The LightStrike+ Robot, authorized by the FDA, is a high-intensity, broad-spectrum UV light robot that effectively reduces microbes on surfaces. With cycle times as fast as 2 minutes, it is customizable for different room types and positions, and its sensors immediately stop the device upon motion detection.

The LightStrike+ Robot has been proven safe and effective through rigorous testing on over 10,000 samples of bacteria and C. diff spores, and its use is supported by 45 peer-reviewed studies. It is now included in the infection control protocols of almost 300 hospitals across the US, with more than 1,200 healthcare facilities worldwide utilising LightStrike robots over 37 million cycles.

Xenex's mission is to save lives and reduce suffering by providing hospitals with an effective disinfection strategy, and their passion for research and improving the world is evident in their work.

Xenex's funding and investors

Xenex Disinfection Services, a company headquartered in San Antonio, Texas, was founded in 2009 by Mark "Tuck" Stibich and Julie Stachowiak, who first met at Johns Hopkins University during their doctoral studies. Xenex has raised $95.32 million over seven rounds of funding, with its latest funding round, a debt round, raising $6.02 million on October 2, 2018. The company has 11 investors, including Sequel Ventures, EW Healthcare Partners, and Essex Woodlands Healthcare Partners.

Xenex manufactures and develops UV light disinfection robots, which assist hospitals in minimising Hospital-Acquired Infections (HAIs). The company's Pulsed Xenon UV light approach destroys more pathogens and in less time than competitors, while also being easy to integrate into hospital cleaning operations. Xenex's system is a portable device that uses pulsed xenon UV light to kill bacteria and viruses in healthcare facility rooms, helping hospitals achieve their HAI reduction goals.

Xenex's robots are currently in service in over 1,500 clients, including the Mayo Clinic, MD Anderson Center, and Stanford University Hospital and Clinics. The company's mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause HAIs. Xenex's Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load associated with an increased risk of HAIs. Since its commercial launch in June 2010, Xenex devices have been included in infection control protocols in almost 300 hospitals across the US.

The company is led by an experienced team of clinicians and executives, with Stibich serving as Chief Scientific Officer and holding over 120 granted patents on infection control approaches.

Xenex's founding and history

Xenex Disinfection Services was founded in 2008 by Mark "Tuck" Stibich and Julie Stachowiak, who met while studying for their doctorates at Johns Hopkins University. Both epidemiologists, they shared a passion for research and a desire to make the world a better place. They wanted to provide healthcare facilities with a more effective way to prevent pathogen transmission and ensure that scientific evidence supported all the company's claims.

Xenex's mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). The company's flagship product is the LightStrike+ Robot, a portable device that uses pulsed xenon UV light to kill bacteria and viruses in healthcare facilities, helping hospitals achieve their HAI reduction goals and safeguard patients, staff, and finances.

Since its commercial launch in June 2010, Xenex devices have been included in infection control protocols in almost 300 hospitals across the US. Headquartered in San Antonio, Texas, Xenex is led by an accomplished team of highly experienced clinicians and executives.

Xenex has raised $95.32 million over seven rounds of funding, with investors including EW Healthcare Partners and Sequel Ventures.

Xenex's products and services

Xenex Disinfection Services is a company that develops ultraviolet room disinfection systems designed to destroy harmful microorganisms, such as bacteria and viruses, in healthcare facilities. Their products aim to reduce hospital-acquired infections (HAIs) and safeguard patients, staff, and healthcare facilities' bottom lines.

Xenex's core product is its patented Pulsed Xenon UV system, which is used in its Germ-Zapping Robot. This robot provides an easy-to-integrate approach to reducing microbial loads in healthcare rooms and areas. The LightStrike™+ Robot is an FDA-authorised microbial reduction robot for the healthcare environment. It is the first and only of its kind, offering cycle times as fast as 2 minutes for vegetative bacteria.

Xenex also offers the LightStrike6 LSMUV6-FT/LSMUV6-SL and the Deactivate Handheld LED Unit as part of its disinfection solutions. In addition to their robots, Xenex provides training and advanced workflow consulting to help speed room turnover and improve throughput.

The company was founded in 2009 by Mark (Tuck) Stibich and Julie Stachowiak, two epidemiologists who met at Johns Hopkins University. Xenex is headquartered in San Antonio, Texas, and its devices are now included in infection control protocols in almost 300 hospitals across the United States.

Xenex's customers and clients

Xenex Disinfection Services has a wide range of customers and clients who have successfully implemented their products and services to improve disinfection processes and patient safety. Here are some examples:

Mayo Clinic

The Mayo Clinic is a well-known healthcare facility that has utilised Xenex's robots to improve disinfection. They reported a 47% reduction in C.diff infection rates using the Pulsed Xenon UV Room Disinfection system.

MD Anderson Center

The MD Anderson Center is another prominent healthcare organisation that has benefited from Xenex's technology. They have achieved successful results in reducing deadly microorganisms and enhancing patient health and satisfaction.

Stanford University Hospital and Clinics

Stanford University Hospital and Clinics have also employed Xenex's solutions. They have likely experienced improved profitability, enhanced patient outcomes, and decreased costs of care due to the efficient disinfection capabilities of Xenex's products.

Hospitals Across the United States

Since its commercial launch in June 2010, Xenex's devices have been incorporated into infection control protocols in nearly 300 hospitals throughout the United States. This widespread adoption demonstrates the trust that healthcare institutions have in Xenex's ability to help them achieve their HAI reduction goals and safeguard patients, staff, and financial viability.

Individual Testimonials

Xenex has received numerous endorsements from individuals in the healthcare industry. For example, Meghann Holmes, RN, CIC, and Samantha Green, RN, Infection Preventionists, praised the LightStrike Robots for enhancing their disinfection process and making patient safety a top priority. Similarly, Necia Kimber, RN, BSN, MHA, CIC, from Infection Control & Prevention, highlighted the significant reduction in C. diff in the environment after integrating Xenex's technology. A Cardiothoracic Surgeon also commended the LightStrike Robots as an effective tool in their battle against pathogens, providing an advantage in the surgical suite.

Frequently asked questions